Metabolic Disorders
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger
The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.
AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate
Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.
As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan
With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.
Wegovy Manufacturing Issues Continue To Hamper Novo Nordisk
Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.
Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds
Wegovy and Saxenda surpass cost effectiveness thresholds at current prices, while two widely unused drugs, Qysmia and Contrave, are cost-effective at accepted benchmarks, according to a draft report from the Institute for Clinical and Economic Review.
Rhythm Eyes Bigger Market For Imcivree Following Phase II Hypothalamic Obesity Promise
The US firm’s Imcivree has impressed with interim mid-stage data from a hypothalamic obesity study, paving the way for pivotal success that could open up a much larger market.
Vertex Builds Type 1 Diabetes Reach And Flexibility With ViaCyte
Vertex will pay $320m to buy rival ViaCyte, which is developing stem cell therapies for type 1 diabetes, to complement internal work on VX-880, the firm announced.
Vertex Diabetes Cell Therapy Back On Track After FDA ‘Hiccup’
The US firm has received the FDA thumbs-up to continue a trial for its novel cell therapy candidate, VX-880, after what was perceived in some circles as an over-cautious decision by the regulator to pause the study in March.
Rhythm Leans On Imcivree Rare Disease Commercialization For New Indication
The company got FDA approval for the drug in Bardet-Biedl syndrome, on top of the existing approval from November 2020 in obesity due to POMC, PCSK1 and LEPR deficiency.
Novo’s Sogroya Impresses In Children With Convenience Advantage Over SOC
The Danish firm’s injectable growth hormone analogue has succeeded in a late-stage study of children with a growth disorder and offers more convenient dosing that could improve adherence.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.